Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Daniel Pavin advises clients on a wide range of transactions involving intellectual property, technology and data.

He has extensive experience advising pharmaceutical, biotechnology, medical device and technology companies in connection with licensing, collaborations and other strategic agreements. He also advises clients in connection with investments, fundraisings and M&A.

Mr. Pavin has a particular focus on digital transformation in the life sciences and healthcare sectors, including digital health transactions, and data-driven and AI drug discovery and development projects.

Mr. Pavin is one of the leaders of Covington’s global, multidisciplinary Digital Health Initiative, which brings together the firm’s considerable resources across the broad array of legal, regulatory, commercial, and policy issues relating to the development and exploitation of digital health products and services.

  • Clinical artificial intelligence company Sensyne Health plc on:
    • a licence and development agreement with Excalibur Healthcare Services, in respect of Sensyne's cloud-based, deep learning, MagnifEye technology, for use with lateral flow diagnostic tests. The initial focus is on use of MagnifEye for COVID-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer and other disease conditions;
    • its exclusive strategic collaboration with, and a $10 million equity investment in, Phesi, Inc, a U.S.-based specialist clinical trials data company, and its £27.5 million equity fundraising;
    • its agreement with Jefferson Health to evaluate the clinical and commercial potential of its GDm-Health™ system in the United States;
    • data protection matters in connection with its £60 million IPO on London’s AIM market; and
    • strategic research and data processing agreements with the Chelsea and Westminster Hospital NHS Foundation Trust, the Oxford University Hospitals NHS Foundation Trust, and the South Warwickshire NHS Foundation Trust.
  • Illumina on its partnership with Genomics England, to sequence up to 500,000 whole genomes for the NHS Genomic Medicine Service.  
  • GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta (γδ) T-cells to develop transformational immunotherapies, on the formation of Adaptate Biotherapeutics, a spin-out company building on GammaDelta’s knowledge to modulate γδ T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.  
  • BenevolentAI, an AI company developing and applying advanced technologies to accelerate the journey from data to medicine, on its acquisition of Proximagen Limited, a Cambridge, UK-based drug discovery and development company. 
  • GammaDelta Therapeutics Limited, on a strategic collaboration with Takeda to develop GammaDelta Therapeutics’ novel T cell platform, which is based on the unique properties of gamma delta (γδ) T cells derived from human tissues.
  • Abingworth on the establishment of and investment in GammaDelta Therapeutics Ltd, an immunotherapy company. GammaDelta Therapeutics has been founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (γδ) T cells.
  • Medical Research Council Technology, a UK-based medical research charity, in the structured sale of a portion of its royalty interests in Keytruda for U.S.$150 million (£115.6 million), the largest royalty monetization by a non-profit institution outside the United States.  
  • AstraZeneca, along with its global biologics research and development arm, MedImmune, on a collaboration with Moderna Therapeutics to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
  • AstraZeneca on its acquisition of the core respiratory business of Takeda.
  • A leading provider of on-demand video streaming services on its successful claim against the developer of the underlying software platform for delivery up of source code.
  • Illumina on its strategic alliance agreement with Genomics England in respect of sequencing genomes of patients with cancer and rare diseases, as part of a four-year UK government project to decode 100,000 human genomes.
  • Isarna Therapeutics GmbH, a German biotechnology company, on a license agreement with Santaris Pharma A/S for access to Santaris' Locked Nucleic Acid technology to develop oligonucleotide product candidates.   
  • Innovacell on a collaboration and licensing agreement with Norgine for Europe (excluding Russia and Turkey), SADC and MENA regions in which Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence.
  • Sanofi on a research collaboration agreement with Danish biotech Gubra ApS focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity.
  • Pharming Group NV on its strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture and commercialisation of new products based on the Pharming technology platform, in which SIPI will have commercialisation rights for the Chinese market for all new products developed and Pharming will retain global rights ex-China.
  • UCB in relation to its strategic partnership with Synosia Therapeutics in which Synosia granted UCB a licence for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications, both compounds being in Phase II clinical development for the treatment of Parkinson’s disease.
  • Minster Pharmaceuticals PLC, an AIM-quoted drug development company specializing in compounds for the treatment of neurological and psychiatric conditions, on intellectual property aspects of its recommended takeover by Proximagen Neuroscience PLC.   
  • Biocompatibles International plc on numerous transactional matters including:   
    • An option agreement with a major multinational Japanese pharmaceutical company in respect of Biocompatibles’ Drug-Eluting Bead Products in Japan;
    • Distribution agreements with (among others) SciClone Pharmaceuticals and RITA Medical Systems, Inc (now AngioDynamics, Inc) in respect of Biocompatibles’ DC and LC Bead Products; and
    • The sale of Biocompatibles’ cardiovascular business to Abbott Laboratories and eyecare business to the Cooper Group.
  • Australian anti-infective drug development company, Biota Holdings Limited, on:   
    • UK intellectual property aspects of its acquisition of the key assets and programs of UK-based antibacterial drug discovery company, Prolysis Limited; and
    • Its collaboration and licence agreement with a major multinational pharmaceutical company headquartered in Europe relating to a series of antivirals aimed at the treatment of respiratory syncytial virus (RSV).
  • A global medical technology company in respect of a dispute regarding endeavors obligations in a patent and know-how licence for stabilization technology.
  • Communications company, Telefónica O2 UK, on document and data retention and data protection matters.   
  • A range of clients, including service providers to the financial services sector, recruitment consultancies, pension trustees and media companies, on responding to data security breaches and potential liabilities arising from those breaches.   
  • The shareholders of Sibelius Software Limited, the world-leading music notation software developer, on its sale to Avid, the world leader in digital media creation tools for film, video, audio, animation, games, and broadcast professionals.

Pro Bono

  • Working with Kids In Need of Defense UK to provide children and young people with pro bono immigration and nationality legal advice and representation.
  • Representing a medical research charity in connection with corporate, commercial and privacy matters.
  • Advising Evidence for Development, a charity dedicated to improving the effectiveness of development aid through economic analysis.

Memberships and Affiliations

  • Mentor on the AstraZeneca and Covington Mentoring Scheme, run in conjunction with Aspiring Solicitors
  • Chambers UK, Life Sciences: Transactional (2012-2021) 
  • IAM Patent 1000 - The World’s Leading Patent Practitioners, Recommended (2012-2020)
  • Who's Who Legal, Life Sciences Transactional   
  • Legal 500 UK, Life Sciences and Healthcare - Band 1 (2021)